317 related articles for article (PubMed ID: 25605837)
1. KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence.
Joensuu H; Rutkowski P; Nishida T; Steigen SE; Brabec P; Plank L; Nilsson B; Braconi C; Bordoni A; Magnusson MK; Sufliarsky J; Federico M; Jonasson JG; Hostein I; Bringuier PP; Emile JF
J Clin Oncol; 2015 Feb; 33(6):634-42. PubMed ID: 25605837
[TBL] [Abstract][Full Text] [Related]
2. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
Joensuu H; Wardelmann E; Sihto H; Eriksson M; Sundby Hall K; Reichardt A; Hartmann JT; Pink D; Cameron S; Hohenberger P; Al-Batran SE; Schlemmer M; Bauer S; Nilsson B; Kallio R; Junnila J; Vehtari A; Reichardt P
JAMA Oncol; 2017 May; 3(5):602-609. PubMed ID: 28334365
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience.
Wozniak A; Rutkowski P; Piskorz A; Ciwoniuk M; Osuch C; Bylina E; Sygut J; Chosia M; Rys J; Urbanczyk K; Kruszewski W; Sowa P; Siedlecki J; Debiec-Rychter M; Limon J;
Ann Oncol; 2012 Feb; 23(2):353-60. PubMed ID: 21527588
[TBL] [Abstract][Full Text] [Related]
4. Impact of KIT and PDGFRA gene mutations on prognosis of patients with gastrointestinal stromal tumors after complete primary tumor resection.
Hou YY; Grabellus F; Weber F; Zhou Y; Tan YS; Li J; Shen KT; Qin J; Sun YH; Qin XY; Bockhorn M; Gerken G; Broelsch CE; Frilling A
J Gastrointest Surg; 2009 Sep; 13(9):1583-92. PubMed ID: 19291337
[TBL] [Abstract][Full Text] [Related]
5. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
[No Abstract] [Full Text] [Related]
6. Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.
Kalfusova A; Linke Z; Kalinova M; Krskova L; Hilska I; Szabova J; Vicha A; Kodet R
Pathol Res Pract; 2019 Dec; 215(12):152708. PubMed ID: 31708372
[TBL] [Abstract][Full Text] [Related]
7. Exon 11 homozygous mutations and intron 10/exon 11 junction deletions in the KIT gene are associated with poor prognosis of patients with gastrointestinal stromal tumors.
Shen YY; Ma XL; Wang M; Zhuang C; Ni B; Tu L; Liu Q; Zhao WY; Cao H
Cancer Med; 2020 Sep; 9(18):6485-6496. PubMed ID: 32697050
[TBL] [Abstract][Full Text] [Related]
8. [Status and clinical implication of c-kit and PDGFRA mutations in 165 cases of gastrointestinal stromal tumor (GIST)].
He HY; Fang WG; Zhong HH; Li Y; Zheng J; Du J; Heng WJ; Wu BQ
Zhonghua Bing Li Xue Za Zhi; 2006 May; 35(5):262-6. PubMed ID: 16776995
[TBL] [Abstract][Full Text] [Related]
9. Molecular spectrum of c-KIT and PDGFRA gene mutations in gastro intestinal stromal tumor: determination of frequency, distribution pattern and identification of novel mutations in Indian patients.
Ahmad F; Lad P; Bhatia S; Das BR
Med Oncol; 2015 Jan; 32(1):424. PubMed ID: 25481675
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic significance of DOG-1 and PKC-θ expression and c-Kit/PDGFRA mutations in gastrointestinal stromal tumours.
Wang C; Jin MS; Zou YB; Gao JN; Li XB; Peng F; Wang HY; Wu ZD; Wang YP; Duan XM
Scand J Gastroenterol; 2013 Sep; 48(9):1055-65. PubMed ID: 23862765
[TBL] [Abstract][Full Text] [Related]
11. Gastric GISTs: Analysis of c-Kit, PDGFRA and BRAF mutations in relation to prognosis and clinical pathological characteristics of patients - A GIRCG study.
Capelli L; Petracci E; Quagliuolo V; Saragoni L; Colombo P; Morgagni P; Calistri D; Tomezzoli A; Di Cosmo M; Roviello F; Vindigni C; Coniglio A; Villanacci V; Catarci M; Coppola L; Alfieri S; Ricci R; Capella C; Rausei S; Gulino D; Amadori D; Ulivi P;
Eur J Surg Oncol; 2016 Aug; 42(8):1206-14. PubMed ID: 27265040
[TBL] [Abstract][Full Text] [Related]
12. KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study.
Rossi S; Gasparotto D; Miceli R; Toffolatti L; Gallina G; Scaramel E; Marzotto A; Boscato E; Messerini L; Bearzi I; Mazzoleni G; Capella C; Arrigoni G; Sonzogni A; Sidoni A; Mariani L; Amore P; Gronchi A; Casali PG; Maestro R; Dei Tos AP
Am J Surg Pathol; 2015 Jul; 39(7):922-30. PubMed ID: 25970686
[TBL] [Abstract][Full Text] [Related]
13. Malignancies associated with GIST: a retrospective study with molecular analysis of KIT and PDGFRA.
Mayr P; Märkl B; Agaimy A; Kriening B; Dintner S; Schenkirsch G; Schneider-Stock R
Langenbecks Arch Surg; 2019 Aug; 404(5):605-613. PubMed ID: 30877378
[TBL] [Abstract][Full Text] [Related]
14. Extra-gastrointestinal stromal tumor arising in the lesser omentum with a platelet-derived growth factor receptor alpha (PDGFRA) mutation: a case report and literature review.
Kanamori K; Yamagata Y; Honma Y; Date K; Wada T; Hayashi T; Otsuki S; Sekine S; Yoshikawa T; Katai H; Nishida T
World J Surg Oncol; 2020 Jul; 18(1):183. PubMed ID: 32703220
[TBL] [Abstract][Full Text] [Related]
15. Morphological Correlates of KIT and PDGFRA Genotypes in Gastrointestinal Stromal Tumour.
Priya V; Kumari N; Krishnani N
Turk Patoloji Derg; 2020; 36(2):116-125. PubMed ID: 31538651
[TBL] [Abstract][Full Text] [Related]
16. Detection of KIT and PDGFRA mutations in the plasma of patients with gastrointestinal stromal tumor.
Kang G; Bae BN; Sohn BS; Pyo JS; Kang GH; Kim KM
Target Oncol; 2015 Dec; 10(4):597-601. PubMed ID: 25735500
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events.
Huss S; Pasternack H; Ihle MA; Merkelbach-Bruse S; Heitkötter B; Hartmann W; Trautmann M; Gevensleben H; Büttner R; Schildhaus HU; Wardelmann E
Hum Pathol; 2017 Apr; 62():206-214. PubMed ID: 28159677
[TBL] [Abstract][Full Text] [Related]
18. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.
Corless CL; Ballman KV; Antonescu CR; Kolesnikova V; Maki RG; Pisters PW; Blackstein ME; Blanke CD; Demetri GD; Heinrich MC; von Mehren M; Patel S; McCarter MD; Owzar K; DeMatteo RP
J Clin Oncol; 2014 May; 32(15):1563-70. PubMed ID: 24638003
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors.
Gao J; Li J; Li Y; Li Z; Gong J; Wu J; Liu N; Dong B; Qi C; Li J; Shen L
Oncotarget; 2016 May; 7(21):30241-9. PubMed ID: 26848617
[TBL] [Abstract][Full Text] [Related]
20. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.
Rossi S; Sbaraglia M; Dell'Orto MC; Gasparotto D; Cacciatore M; Boscato E; Carraro V; Toffolatti L; Gallina G; Niero M; Pilozzi E; Mandolesi A; Sessa F; Sonzogni A; Mancini C; Mazzoleni G; Romeo S; Maestro R; Dei Tos AP
Oncotarget; 2016 May; 7(21):30109-18. PubMed ID: 27097112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]